Keywords
cardiovascular disease
diabetes mellitus
How to Cite
Abstract
Introduction: Diabetes mellitus and cardiovascular diseases remain the leading causes of death worldwide. There are approximately 366 million people with diabetes globally, and by 2030, it is projected that this number will reach 520 million, or 6.3% of the world's population, affected by diabetes. Dyslipidemia and diabetes are the main contributors to cardiovascular diseases. Diabetic dyslipidemia is characterized by disturbances in all lipid fractions (increased triglycerides, increased LDL-cholesterol, and low HDL-cholesterol levels).
Purpose of the study: This study aimed to assess hyperlipidemia as a risk factor for cardiovascular disease in patients with diabetes Mellitus.
Materials and Methods: The study was a prospective cohort ("cross-sectional").
Results: A total of 200 participants were included: 100 patients with diabetes mellitus (60 with type 1 and 40 with type 2), and 100 healthy individuals serving as controls. Among the diabetes patients (100), 45 (45%) were female, with a mean age of 58.00 ± 14.00 years, while 55 (55%) were male, with a mean age of 59.60 ± 12.00 years. The control group comprised 100 voluntary blood donors, 45 (45%) women and 55 (55%) men, with a mean age of 58.40 ± 13.60 years. The results are shown in the following tables (numbers 3-6).
Conclusion: Dyslipidemia and hyperglycemia are the principal risk factors and are independent of the development of premature atherosclerosis and cardiovascular disease. Treating primary or secondary dyslipidemia early is crucial and can significantly help prevent early atherosclerotic processes and cardiovascular diseases. Recent studies on the treatment of dyslipidemia have shown a strong positive effect of statins (40 mg dose), which appear to help prevent cardiovascular disease.
References
Ogbera O. Azenabor O. Lipoprotein(a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM. Diabetologija & Metabolic Syndrome 2010; 2:51.
Tarkun I, et al. Lipoprotein (a) concentration in patients with type 2 diabetes mellitus without cardiovascular disease: relationship to metabolic and diabetic complications. Nutr Metab Cardiovasc Dis. 2002 Jun; 12 (3): 127–131.
Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996;335(14):1001–1009.
Tonkin A., Simes R., Sharpe N., et al. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998;339(19):1349–1357.
Hindy G., Engström G., Larsson S.C., et al. Stroke Genetics Network (SiGN) Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes: A Mendelian Randomization Study. Stroke. 2018;49(4):820–827.
Gupta M. Assessment of Lipid Profile of Patients with Acute Myocardial Infarction: A Comparative Study. Journal of Medical Science and Clinical Research. 2018;06:483–6.
Ravnskov U., Diamond D.M., Hama R., et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open. 2016;6(6):e010401.
Philip-Ephraim EE, Charidimou A, Kajogbola GA. Quadriparesis due to simultaneous occurrence of hemorrhagic and ischemic stroke. International Journal of Stroke: Official Journal of the International Stroke Society. 2015;10(2):E11.
Blekkenhorst L.C., Prince R.L., Hodgson J.M., Lim W.H., Zhu K., Devine A., Thompson P.L., Lewis J.R. Dietary saturated fat intake and atherosclerotic vascular disease mortality in older women: a prospective cohort study. Am. J. Clin. Nutr. 2015;101(6):1263–1268.
Grant RW, Meigs JB: Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care. 2007, 30: 479-484.10.2337/dc06- 1961
Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH: Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007, 100: 1499–1501. 10.1016/j.amjcard.2007.06.058.
Klingman D, Williams SA, Benner JS, Smith TW, Ahn J, O'Donnell JC: Gauging the treatment gap in dyslipidemia: findings from the 1999–2000 National Health and Nutrition Examination Survey. Am Heart J. 2005, 150: 595-601.
Davidson MH: Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006, 12 (15 Suppl): S405-S411.
Maurus Marques de Almeida Holanda, et al. PLASMA LIPOPROTEIN (A) LEVELS –A comparison between diabetic and non diabetic patients with acute ischemic stroke. Arq Nuropsiquiatr 2004;62(2-A): 233-236.
Nawawi HM, Muhajir M, et al. Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein(a) levels in diabetic patients. Diabetes Res Clin Pract. 2002; 56:221-227.
Chahil TJ and Ginsberg HN (2006). Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35: 491–510.
American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 28 (Suppl. 1): S4-S36, 2005.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364:685 696, 2004
Sever PS, Dahlöf B, Poulter Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT investigators: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes. Diabetes Care28: 1151-1157,2005.
Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for prevention of coronary disease. N Engl J Med 345:1583 -1592, 2001.
American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care 26 (Suppl. 1): S51-S61, 2003.
American Diabetes Association: Nutrition principles and recommendations in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1): S36–S46, 2004